Furthermore, in the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER; details at www.ClinicalTrials.gov; NCT00527943) study, vorapaxar reduced the hazard of first myocardial infarction of any type in patients who were treated within 24 h of having symptoms of a cardiovascular event. Here, F2R is linked to acute coronary syndrome.